Skip to main content

Table 6 Nanocapsule characteristics and information

From: Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy

Shell ligand Particle size (nm) a Zeta potential (meV) b Morphology c Cargo d Sequence e
Tenfibgen 27.7 ± 4.6 −7.4 ± 4.2 Uniform, single capsules siCDK11 5′-gagcgagcagcagcgugugdTdT-3′
27 kDa
Tenfibgen 20.7 ± 5.2 −1.7 ± 2.4 Uniform, single capsules siCK2 5′-auacaacccaaacuccacaudTdT-3′
27 kDa
Tenfibgen 16.2 ± 2.4 −7.8 ± 4.2 Uniform, single capsules siCON1 5′-uagcgacuaaacacaucaauudTdT-3′
27 kDa
  1. CDK, cyclin-dependent kinase; CK2, casein kinase 2; si, small interfering; TEM, transmission electron microscopy. aMean ± standard deviation of the average elliptical diameter determined from TEM micrographs measuring at least 20 nanocapsules. bAverage surface charge measured by dynamic light scattering from two different preparations across a 20 V potential in 1 mM KCl at 2 μg/ml. Data shown as the mean ± standard error of 15 independent measurements. cMorphology of all nanocapsules determined by visual atomic force microscopy and TEM observation as uniform, single capsules. dTBG-siCDK11, siCK2, and siCON1 encapsulation efficiencies mean of 54.0%, 86.8%, and 69.2%, respectively, observed by Burton analysis relative to unencapsulated siRNA. eSense strand sequence.